Vimarsana
Biggest News Aggregation in the World

Page 6 - Alp News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Alp. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Alp Today - Breaking & Trending Today

ALP Utilities announces 2024 rate adjustments - Vimarsana News

ALP Utilities announces 2024 rate adjustments

(Alexandria, MN)--During the November 20 meeting, the Alexandria Board of Public Utilities approved a 5% overall increase to electric rates and a 9% increase to water rates for 2024. The

Q&A: Combination OCA-Bezafibrate for PBC, with Cynthia Levy, MD - Vimarsana News

Q&A: Combination OCA-Bezafibrate for PBC, with Cynthia Levy, MD

Cynthia Levy, MD, professor of medicine at the University of Miami, provided further insight into unmet needs in PBC, the use of OCA-bezafibrate in PBC, and the significance of results from a pair of phase 2 studies presented at The Liver Meeting.

Phase 2 Studies Show OCA-Bezafibrate Achieves Biochemical Remission, ALP Reduction - Vimarsana News

Phase 2 Studies Show OCA-Bezafibrate Achieves Biochemical Remission, ALP Reduction

Topline data from Study 747-213 and a planned interim analysis from Study 747-214 were presented at The Liver Meeting 2023 from the American Association for the Study of Liver Diseases.

At CII organized International Railway Equipment Exhibition (IREE) - ALP Aeroflex launches, made in India, New Age insulation to suit requirement of high speed rail coaches - Vimarsana News

At CII organized International Railway Equipment Exhibition (IREE) - ALP Aeroflex launches, made in India, New Age insulation to suit requirement of high speed rail coaches

Pti: At CII organized International Railway Equipment Exhibition (IREE) - ALP Aeroflex launches, made in India, New Age insulation to suit requirement of high speed rail coaches

Seladelpar Achieves Primary, Secondary Endpoints in Phase 3 RESPONSE Trial - Vimarsana News

Seladelpar Achieves Primary, Secondary Endpoints in Phase 3 RESPONSE Trial

Results from RESPONSE show seladelpar may improve measures of disease activity and reduce symptom burden in patients with PBC.